###begin article-title 0
Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships
###end article-title 0
###begin p 1
Present address: Department of Biochemistry, Faculty of Science, The Chinese University of Hong Kong, Hong Kong.
###end p 1
###begin p 2
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
###end p 2
###begin p 3
###xml 251 257 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 572 578 572 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 583 589 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 889 895 889 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 949 955 949 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1060 1065 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 1070 1076 1070 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
Osteogenesis imperfecta (OI), also known as brittle bone disease, is a clinically and genetically heterogeneous disorder primarily characterized by susceptibility to fracture. Although OI generally results from mutations in the type I collagen genes, COL1A1 and COL1A2, the relationship between genotype and phenotype is not yet well understood. To provide additional data for genotype-phenotype analyses and to determine the proportion of mutations in the type I collagen genes among subjects with lethal forms of OI, we sequenced the coding and exon-flanking regions of COL1A1 and COL1A2 in a cohort of 63 subjects with OI type II, the perinatal lethal form of the disease. We identified 61 distinct heterozygous mutations in type I collagen, including five non-synonymous rare variants of unknown significance, of which 43 had not been seen previously. In addition, we found 60 SNPs in COL1A1, of which 17 were not reported previously, and 82 in COL1A2, of which 18 are novel. In three samples without collagen mutations, we found inactivating mutations in CRTAP and LEPRE1, suggesting a frequency of these recessive mutations of approximately5% in OI type II. A computational model that predicts the outcome of substitutions for glycine within the triple helical domain of collagen alpha1(I) chains predicted lethality with approximately90% accuracy. The results contribute to the understanding of the etiology of OI by providing data to evaluate and refine current models relating genotype to phenotype and by providing an unbiased indication of the relative frequency of mutations in OI-associated genes.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 431 437 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 441 447 429 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 671 676 651 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 681 687 661 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 689 690 669 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C1">1</xref>
###xml 691 692 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C3">3</xref>
###xml 1058 1064 1034 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 1066 1072 1042 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1074 1079 1050 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 1084 1090 1060 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 1241 1242 1217 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C1">1</xref>
###xml 1243 1244 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C2">2</xref>
###xml 1245 1246 1221 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C4">4</xref>
###xml 366 373 <span type="species:ncbi:9606">infants</span>
Osteogenesis imperfecta (OI), also known as brittle bone disease, is a heterogeneous disorder characterized by susceptibility to fracture. The disease varies in severity from mild (OI type I) to perinatal lethal (OI type II) and exhibits both autosomal dominant and recessive inheritance patterns. The dominantly inherited forms that account for approximately90% of infants and adults with OI result from heterozygous mutations in COL1A1 or COL1A2, the genes that encode the proalphal(I) and proalpha2(I) chains of type I collagen, the major structural protein of bone. Recessively inherited OI results in many cases from homozygous or compound heterozygous mutations in CRTAP and LEPRE1 (1-3), which encode cartilage-associated protein and leucine proline-enriched proteoglycan (leprecan; prolyl-3-hydroxylase-1), respectively. These two proteins are part of a complex that hydroxylates a single proline residue at position 986 of the triple helical domain of the proalpha1(I) chain of collagen during its biosynthesis. Mutations in each of the four genes, COL1A1, COL1A2, CRTAP and LEPRE1, lead to the production of type I collagen molecules that undergo excessive post-translational modification, at least in cultured dermal fibroblasts (1,2,4).
###end p 5
###begin p 6
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C6">6</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C8">8</xref>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C6">6</xref>
###xml 1174 1175 1170 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C9">9</xref>
###xml 1336 1338 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C10">10</xref>
###xml 1339 1341 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C12">12</xref>
The relationship between the clinical severity of OI and the causative mutations is only partially understood, despite the availability of mutation sequences from >800 individuals with OI (5). The mildest forms of OI generally result from heterozygous mutations that lead to the loss of mRNA from one COL1A1 allele due to the presence of premature termination codons in the coding sequence of that allele (6-8). Different classes of mutations (single codon nonsense mutations, frameshift mutations and splice site mutations that result in use of out-of-frame cryptic splice sites) can all lead to activation of the nonsense-mediated mRNA decay pathway (6). In the more severe forms of OI in which there is often bone deformity, increased fracture rate, dentinogenesis imperfecta and short stature, the most frequent mutations result in substitution of the glycine residue in almost any of the 338 Gly-X-Y tripeptide motifs found in the triple helical region of each of the proalpha chains. For these mutations, it appears that the chain in which the mutation occurs, the position of the substituted glycine and the substituting residue all contribute to phenotypic outcome (9). Yet the nature of these relationships is not yet evident. This may reflect the possibility that different mutations result in lethality by distinct pathways (10-12).
###end p 6
###begin p 7
###xml 485 491 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 502 508 502 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 627 633 627 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
Given the diversity of mechanisms underlying the lethal forms of OI, understanding the relationship between genotype and phenotype requires mutation detection and clinical data from a larger number of individuals with OI type II than currently available. To initiate this process, we identified the disease-associated mutations in 62 subjects with OI type II. In 59 cases we found heterozygous mutations in the type I collagen genes, of which 23 of the distinct causative mutations in COL1A1 and 15 in COL1A2 are novel. In three samples without collagen mutations, we found homozygous inactivating mutations in CRTAP (one) and LEPRE1 (two individuals homozygous for the same West African allele). Since the subjects were selected based only on phenotype and the production of abnormal type I procollagen molecules, this provides an unbiased indication of the frequency of mutations in these genes in OI type II. The novel collagen mutations provide a valuable addition to the set of known mutations available for studying genotype-phenotype relationships.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
COL1A1 and COL1A2 SNPs
###end title 9
###begin p 10
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDN374TB1">1</xref>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDN374TB2">2</xref>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 529 535 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 581 587 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 603 609 603 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C13">13</xref>
###xml 940 946 940 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 963 969 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1061 1067 1061 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 1097 1103 1097 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1280 1282 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C13">13</xref>
###xml 818 825 <span type="species:ncbi:9606">patient</span>
A total of 203 distinct genomic sequence variations were identified in the type I collagen genes among the 63 subjects with OI type II, 98 in COL1A1 and 105 in COL1A2 (Table 1). This includes 142 SNPs () and 61 mutations and non-synonymous sequence variants of unknown significance (Table 2). Of the 142 SNPs, 35 are novel: 17 in COL1A1 and 18 in COL1A2. Of the 76 common SNPs with minor allele frequency (MAF) >0.05 listed in dbSNP which are located within the genomic regions of the resequencing effort (25 in COL1A1 and 51 in COL1A2), all but three (rs41317349 and rs2586494 in COL1A1 and rs17073 in COL1A2) are seen in our sample set. The SNPs rs41317349 and rs2586494 are particularly common in the African-American and Asian populations, respectively (13), so their absence may reflect the ethnicities in our OI patient cohort that is largely Caucasian. Approximately 90% of the identified SNPs in each gene are intronic (53 of 60 in COL1A1 and 73 of 82 in COL1A2), and only one non-synonymous SNP was recognized in each gene, rs1800215 (p.Ala1075Thr) in COL1A1 and rs42524 (p.Ala549Pro) in COL1A2. The rs42524 SNP is present at frequencies of 17.7, 26.0, 9.38 and 30.2% in African-American, Hispanic, Chinese and Caucasian populations of healthy individuals, respectively (13). In the same study, rs1800215 was found at a frequency of 6.25% in African-American population (negligible in other ethnic groups).
###end p 10
###begin p 11
Distribution of distinct genomic sequence variations in type I collagen genes
###end p 11
###begin p 12
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
aIncludes causative mutations and sequence variants of unknown significance.
###end p 12
###begin p 13
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
COL1A1 and COL1A2 mutations
###end p 13
###begin p 14
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
aReferences are listed for previously reported mutations; this field is left blank for novel mutations.
###end p 14
###begin p 15
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
bReported in both lethal and non-lethal OI cases.
###end p 15
###begin p 16
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
cReported as OI type III.
###end p 16
###begin p 17
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 141 143 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C13">13</xref>
###xml 152 153 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDN374TB3">3</xref>
###xml 647 649 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C14">14</xref>
Three intronic SNPs in COL1A2 with MAF approximately0.05 or greater among the OI individuals were not seen previously in our healthy cohort (13) (Table 3). One, with an MAF of 4.1%, is a novel SNP, whereas the other two were reported previously. rs34026686 has only one submitter listed in dbSNP and no allele frequency information, suggesting that it could be a rare allele. However, in our OI sample set it has an MAF of 14.4%. rs10228528 has an MAF of 4.8% among the OI subjects and is listed with an MAF of only 0.8% among the Caucasians (CEU), although it is known to be more common in Han Chinese (CHB) and Yoruba African (YRI) populations (14).
###end p 17
###begin p 18
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
Common SNPs in COL1A2
###end p 18
###begin p 19
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
aAccording to dbSNP build 129.
###end p 19
###begin title 20
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
COL1A1 and COL1A2 mutations
###end title 20
###begin p 21
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDN374TB2">2</xref>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 351 357 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 368 374 368 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 985 991 985 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1403 1409 1403 1409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 1627 1633 1627 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1793 1795 1789 1791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C15">15</xref>
###xml 1903 1909 1899 1905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 2030 2036 2026 2032 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 2041 2047 2037 2043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 2248 2254 2236 2242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 2259 2265 2247 2253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 2282 2283 2270 2271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
We identified mutations in type I collagen genes in 59 of the 63 samples (Table 2). In one sample (C2) in which protein studies indicated a rearrangement in COL1A1, no mutation was detected in genomic DNA but cDNA analysis revealed a nine-exon deletion (exons 40-48). Of the 59 samples in which collagen mutations were identified, 37 had mutations in COL1A1 and 22 in COL1A2. Among the 34 distinct COL1A1 causative mutations, 26 resulted in substitution for a glycine within the Gly-X-Y triplet domain of the triple helix, four altered splice sites and resulted in exon skipping, one resulted in exon skipping from a deletion spanning coding and intronic sequence, one was a nine-exon deletion from genomic DNA, one was a duplication of nine nucleotides and the last (p.Asp1413Asn) altered a single residue in the carboxyl-terminal propeptide. Our unpublished studies suggest that this last mutation interferes with chain association. Among the 22 causative mutations we identified in COL1A2, 13 resulted in substitution for triple helix glycine residues, three were deletions of different 18 bp fragments, two were splice site mutations that resulted in exon skipping, one was a 3 bp duplication and one a 9 bp deletion. Two additional mutations resulted in exon skipping: one deletion spanning coding and intronic sequence and the other one not yet resolved. In sample H2, we identified a mutation in COL1A1 that is most likely responsible for the OI type II phenotype c.1364G>A, p.Gly455Asp, Gly277Asp in the triple helix and, in addition, a second mutation, c.700C>T, p.Arg234Cys, Arg144Cys in the triple helical domain of COL1A2. Substitutions of arginine by cysteine in the triple helical domain of proalpha1(I) chains has been associated with classical forms of Ehlers-Danlos syndrome (15). We have not been able to study parental samples to determine if there is a phenotype associated with the COL1A2 sequence alteration. The 38 novel, causative mutations represent a 24% addition to the set of 159 distinct mutations in COL1A1 and COL1A2 associated with lethal forms of OI published by the OI consortium (99 and 44 unique substitutions for glycine in alphal(I) and alpha2(I), respectively, and seven and nine unique splicing mutations in COL1A1 and COL1A2, respectively) (5).
###end p 21
###begin p 22
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 198 204 198 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 264 270 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C16">16</xref>
###xml 819 825 819 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 992 993 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 968 975 <span type="species:ncbi:9606">patient</span>
As seen previously, the most common mutations are missense mutations that result in substitution for triple helical glycine residues and represent 80 and 60% of the observed mutations in COL1A1 and COL1A2, respectively, in this set. Twice as many were observed in COL1A1 as in COL1A2 (26 versus 13), consistent with the set of mutations reported by the OI consortium, in which 67% of the lethal glycine missense mutations occurred in COL1A1 (5). We also identified mutations affecting splice sites, insertions and deletions in the triple helical region of multiples of three amino acids and mutations in repetitive regions, all of which have been discussed previously regarding OI (5,16). Sixteen of the 18 mutations previously seen were reported in at least one case of lethal OI. Although c.3423+2T>A (IVS47+2T>A) in COL1A1 has not been described previously, mutation of the adjacent G of the obligate GT at the donor site (c.3423+1G>A, IVS47+1G>A) was found in one patient with lethal OI (5).
###end p 22
###begin p 23
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1236 1238 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C17">17</xref>
###xml 1103 1110 <span type="species:ncbi:9606">patient</span>
###xml 1207 1214 <span type="species:ncbi:9606">patient</span>
The data set also includes some unique features. The COL1A2 mutation c.1369_1370GG>CT, p.Gly457Leu is the first observed leucine for glycine substitution in a type I collagen gene and the only known example of a dinucleotide mutation in a glycine codon in this gene. The c.700C>T, p.Arg234Cys mutation is the first mutation in which arginine is replaced by cysteine in the triple helical domain of proalpha2(I). Four additional individuals with substitutions for glycine in proalpha1(I) chains also had a second amino substitution that affected a non-glycine residue in proalpha1(I) chains, three in the triple helical region (p.Glu288Ala, Glu110Ala in the triple helix, p.Ala390Thr, Ala212Thr in the triple helix and p.Asn855His, Asn677His in the triple helix) and one in the N-terminal propeptide (p.Pro146Thr). None of these variations have been reported previously although the p.Ala390Thr was seen in one other individual in the diagnostic setting (unpublished data). The contribution of the non-glycine substitution to the phenotype is not known; however, p.Glu288Lys (c.862G>A) was observed in a patient with OI type I who also had a p.Asp1219Glu in the C-propeptide cleavage site, as well as in the patient's unaffected parent (17), suggesting that substitution of the glutamic acid, at least with lysine, does not cause lethal disease. It is not known whether the pairs of mutations are co-allelic.
###end p 23
###begin title 24
Phenotype prediction for glycine substitutions in proalpha1(I)
###end title 24
###begin p 25
We are developing a computational method for predicting OI phenotype of collagen mutations.
###end p 25
###begin p 26
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 356 357 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDN374TB4">4</xref>
###xml 651 657 643 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
The mutations reported here provide an important opportunity to evaluate the current implementation of the model, which was trained on the OI consortium mutations (5), on new data. Of the 29 patients with mutations resulting in substitution of a triple helical glycine in proalpha1(I) chains, the clinical outcome in 26 (90%) is predicted correctly (Table 4). Of the 17 unique, novel mutations not included in the training set, 15 (88%) were classified correctly. The model can also be applied to serine and cysteine substitutions for glycine in the triple helical region of proalpha2(I) but no novel mutations of this type were identified. The three COL1A1 mutations with incorrect predictions are (i) p.Gly353Asp, Gly175Asp in the triple helix, which lies one glycine N-terminal to the model's cutoff between lethal and non-lethal, (ii) a rare lethal alanine substitution and (iii) p.Gly866Ser, Gly688Ser in the triple helix, which is non-lethal in five of six previously observed cases.
###end p 26
###begin p 27
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
Prediction of lethality for COL1A1 glycine missense mutations
###end p 27
###begin p 28
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
ana, not applicable.
###end p 28
###begin title 29
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
LEPRE1 and CRTAP mutations
###end title 29
###begin p 30
###xml 327 333 327 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 469 470 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C14">1</xref>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 538 544 <span type="species:ncbi:9606">infant</span>
We found no mutations in type I collagen genes in four samples and in three of those we identified mutations in genes in which mutations were recently recognized to give rise to recessive forms of severe/lethal OI. In two of those samples, D1 and D3, there is homozygosity for a recently recognized splice site mutation in the LEPRE1 gene (c.1080+1G>T, IVS5+1G>T) that is of West African origin and is a cause of lethal OI in the African-American community in the USA (1). The ethnic origin of the two families was not stated. In a third infant, C3, there was homozygosity for a splice site mutation in the CRTAP gene (c.471+2C>A, IVS1+2C>A). No consanguinity was reported in the parents.
###end p 30
###begin p 31
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 379 385 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 438 440 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C18">18</xref>
###xml 441 443 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C19">19</xref>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
Based on the small number of patients in our set with mutations in the LEPRE1 and CRTAP genes, an estimate of the proportion of OI type II patients with recessive mutations in these two genes is 4.8% (90% confidence interval 1.5-12.4%). This extends an earlier estimate that CRTAP mutations cause approximately2-3% of cases of lethal OI (2). Because of the measured frequency of LEPRE1 heterozygosity in the African-Americans in the USA (18,19), these mutations may account for a significant proportion of the severe forms of OI in the USA among that group.
###end p 31
###begin title 32
DISCUSSION
###end title 32
###begin p 33
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 275 281 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
We have identified mutations in samples from 62 subjects with OI type II in whose DNA we sequenced the complete coding regions and flanking intronic regions of the two type I collagen genes, COL1A1 and COL1A2. In these samples, 37 had causative mutations in COL1A1 and 22 in COL1A2, of which 38 distinct mutations had not been reported previously, a 24% addition to the published set of unique missense and splicing mutations in these two genes associated with a lethal phenotype (5). Among the four individuals in whom we did not identify mutations in type I collagen, we found one who was homozygous for a CRTAP inactivating mutation and two who were homozygous for a known LEPRE1 mutation common in the African-American population derived from West Africa. One sample remains incompletely characterized but these cells make abnormal type I collagen molecules. Since the samples were selected by two criteria, a clinical picture consistent with a lethal OI phenotype (although some were identified by ultrasound in the second trimester) and cells that made overmodified type I collagens, these results provide an estimate of the relative frequencies of the spectrum of mutations associated with lethal OI.
###end p 33
###begin p 34
###xml 485 494 481 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis&#8211;trans</italic>
###xml 527 532 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 537 543 533 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 556 557 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C1">1</xref>
###xml 558 559 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C3">3</xref>
###xml 560 562 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C18">18</xref>
###xml 563 565 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C20">20</xref>
###xml 720 722 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C12">12</xref>
###xml 723 725 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C21">21</xref>
###xml 765 767 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C22">22</xref>
###xml 798 800 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C23">23</xref>
###xml 863 864 859 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 865 867 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C24">24</xref>
The data suggest that there are multiple pathways that lead to lethality. We identified mutations in OI type II subjects likely to cause impaired post-translational modification of procollagen either because of (i) altered sequences in the triple helical domain of the proalpha chains of type I collagen, (ii) impaired chain association as a result of mutations in the carboxyl-terminal propeptide or (iii) alterations in helix propagation that result from failure to bring the prolyl cis-trans isomerase to the molecule (e.g. CRTAP and LEPRE1 mutations) (1-3,18,20). Mutations that alter the sequences of the triple helical domains of the chains of type I procollagen can affect the thermal stability of the molecules (12,21), interfere with secretion efficiency (22), disrupt the chain register (23) or interfere with ligand binding or other interaction sites (5,24).
###end p 34
###begin p 35
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C12">12</xref>
Models relating genotype to phenotype must capture the diversity of these mechanisms. We allow for this complexity by using a composite predictive model (12). The high accuracy in predicting the lethality of the newly sequenced mutations is consistent with the hypothesis that substitutions of glycine by serine and mutations that substitute bulky amino acids for glycine carboxy-terminal to residue 178 in the triple helical region of proalpha1(I) differ in the manner or extent to which they disrupt collagen structure or function. Triple helix position 178 was modeled as the end of the predominantly non-lethal N-terminal region based on available data. The newly identified lethal mutation Gly175Asp suggests that position 175 may be a better cutoff. Because the current data set is limited to OI type II mutations, a more complete evaluation of the model requires non-lethal cases. Additional mutations are needed to refine other imprecise aspects of the model including whether the cutoff position depends on the residue replacing glycine and the determinant of lethality of substitutions of glycine by cysteine in the proalpha1(I) chains. The use of the composite model framework will allow incorporation of other features that may contribute to lethality, such as individual variation and sites of functional importance, when sufficient data are available.
###end p 35
###begin p 36
###xml 367 368 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 465 467 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C25">25</xref>
###xml 468 470 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C26">26</xref>
###xml 651 653 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C27">27</xref>
###xml 578 583 <span type="species:ncbi:10090">mouse</span>
Exceptions to this model may have implications for our understanding of collagen biology. For example, the model misclassifies Gly370Ala in the triple helix of proalpha1(I) as non-lethal. This suggests that a region around residue 370 may have important function and that its disruption can be lethal. Indeed, substitution of the glycine at 376 by alanine is lethal (5). This region overlaps a binding site for a small proteoglycan (decorin) on collagen molecules (25,26), but it seems unlikely that disturbance of binding of decorin, by itself, is lethal as a decorin knockout mouse does not have OI, despite dramatic alterations in fibrillogenesis (27).
###end p 36
###begin p 37
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C26">26</xref>
###xml 641 647 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 798 804 798 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
It was proposed recently that some regions of the triple helical domain of type I collagen molecules may lack mutations or have exclusively lethal mutations because disruption interferes with a critical function (although these functions have not been clearly identified) (5). Four of the novel mutations in COL1A1, which result in the substitutions Gly706Ser, Gly718Asp, Gly799Asp and Gly916Ser in the triple helical domain, lie within 'lethal-only' regions that overlap the proposed major ligand binding regions MLBR2 and MLBR3 (5,26). Interestingly, Gly688Ser, present in both lethal and non-lethal cases, lies near the edge of MLBR2. In COL1A2, three novel mutations were identified, which fall into lethal-only regions 2 (Gly472Val), 6 (Gly766Val) and 7 (Gly865Asp). In contrast, mutations in COL1A1 that alter residues in triple helix regions 328-346 and 418-436, proposed to be of critical importance due to a lack of observed mutations (5), contain four mutations in our data set (Gly331Val, Gly424Arg, Gly427Arg and Gly436Arg), suggesting that the previous absence of mutations was due to sampling. It is clear that to this point sampling of the almost 2000 possible substitutions of triple helical glycines by other residues in each chain is sufficiently incomplete that it is difficult to draw broad conclusions about the function of particular regions of the triple helical domain based on the absence of mutations.
###end p 37
###begin p 38
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C9">9</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C12">12</xref>
###xml 671 672 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 836 842 832 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 991 997 987 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 1365 1371 1361 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 755 762 <span type="species:ncbi:9606">infants</span>
###xml 1097 1104 <span type="species:ncbi:9606">infants</span>
Of the substitutions for glycine in the triple helical domain encoded by COL1A1 identified here, 16 of the 26 distinct mutations are novel. According to published models (5,9,12), almost all substitutions of glycine by valine, aspartic acid, glutamic acid, arginine and tryptophan between residues 178 and 1012 of the triple helix in proalpha1(I) chains should be lethal. Using codon substitution tables, this suggests that a minimum of 900 of the possible non-synonymous mutations in this region will have a lethal effect. Only 100 distinct lethal glycine substitutions in this region were reported previously, including 49 replacements by alanine, serine and cysteine (5). With the relatively low coverage of these mutations to date, most newly studied infants with lethal OI will have previously unrecognized mutations. Mutations in COL1A2 are less likely to be lethal, and it has been more difficult to locate the domains in which they occur. Of the mutations identified here, 13 of the COL1A2 mutations resulted in substitutions for glycine. Of these, six have been previously encountered in infants with lethal OI but the remaining seven were seen for the first time and six of them fell in domains of the triple helix not previously thought to carry lethal mutations. This suggests that there are still too few lethal mutations, or mutations overall, in the COL1A2 gene to accurately predict the outcome on the basis of any proposed model.
###end p 38
###begin p 39
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
Nearly 10% of the subjects in this study (five of 59) with a type I collagen mutation have a second missense alteration, including one individual with a mutation in both COL1A1 and COL1A2. Although the glycine substitution itself is probably sufficient for lethality in these cases, the additional variations may influence the phenotype resulting from less disruptive mutations. Complete sequencing of both genes and reporting of all sequence variations found will be important for assessing the role of multiple mutations in the development of disease.
###end p 39
###begin p 40
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 62 67 <span type="species:ncbi:9606">child</span>
These studies indicate that recurrence in families in which a child with lethal OI is born is increased as a result of parental carrier status for recessive mutations in addition to the well-known risk of parental mosaicism for dominant mutations. For mutations in the COL1A1 gene, it is clear that substitution of glycine residues by large amino acids carboxyl-terminal to position 178 in the triple helical domain of the proalpha1(I) chains carries a high risk of lethal outcome, something that can be transferred to clinical utility. It is clear that many effects of mutations on behavior of collagen molecules need to be taken into account when determining how they result in lethal mutations. Even in the absence of well-defined pathways and mechanisms, the accumulation of mutations with associated clinical data is an important part of providing the basis for rational counseling of families and represents the first step in forming a truly informative model for how mutations result in phenotypes.
###end p 40
###begin title 41
MATERIALS AND METHODS
###end title 41
###begin title 42
Subject population
###end title 42
###begin p 43
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C22">22</xref>
###xml 1127 1134 <span type="species:ncbi:9606">Patient</span>
We selected 64 DNA samples from unrelated individuals from the Connective Tissue Biopsy Program Repository, an IRB approved activity at the University of Washington that allows further analysis of stored samples. The referral diagnosis for all selected samples was a lethal form of OI. For all samples we had screened cultured fibroblasts for the production of and structure of type I procollagen (22) and cells from all made abnormal proteins. One sample had DNA that failed to amplify (D5). Of the remaining 63, 27 were from fetal samples of <24 weeks gestation. In all instances, the ultrasound picture or post-termination or post-spontaneous delivery radiographs were consistent with the diagnosis of OI type II-minimal calvarial mineralization, very short and bowed limbs, multiple rib fractures. Among the remaining 36 samples, there was no clinical information for one, one that left the hospital at 15 days and for whom there was no follow-up information, and for the remainder there were radiographs or clinical photographs consistent with the diagnosis of a lethal form of OI, with the usual diagnosis of OI type II. Patient descriptions are summarized in . Data on ethnic background were absent for virtually all samples.
###end p 43
###begin p 44
For two of the samples (C3 and D1) there was a record of familial recurrence of lethal OI. For two others (A3, C2), it was noted that the father had a milder form of OI, OI type III or III/IV. No consanguinity was noted in either family. No prior history of OI was noted in any of the remaining instances.
###end p 44
###begin title 45
Collagen gene sequencing and variant detection
###end title 45
###begin p 46
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C13">13</xref>
###xml 93 100 <span type="species:ncbi:9606">patient</span>
###xml 379 384 <span type="species:ncbi:10090">mouse</span>
###xml 389 394 <span type="species:ncbi:9606">human</span>
Genomic DNA was isolated from peripheral blood using standard extraction protocols. For each patient, a total of 14 and 23 kb of genomic DNA for COL1A1 and COL1A2, respectively, were sequenced including all coding regions, intron sequences for at least 100 bp on either side of each exon and evolutionarily conserved domains in non-coding regions (>75% sequence identity between mouse and human). Primer sequences, PCR conditions and sequence coordinates of each fragment are published elsewhere (13). All primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA).
###end p 46
###begin p 47
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C14">14</xref>
Sequence traces were aligned with the GenBank reference sequences of the COL1A1 genomic DNA (AF017178) and cDNA (NM_000088.3), and the COL1A2 genomic DNA (AF004877.1) and cDNA (NM_000089.3). Sequence variations were identified and confirmed by detection with two different analysis programs: Sequencher v4.8 (GeneCodes Corp., Ann Arbor, MI, USA) and Mutation Surveyor v3.1 (SoftGenetics LLC., State College, PA, USA). Automatic calls were verified by inspection. All newly identified variants were deposited in dbSNP (14) under the submitter handle UCSF_HG. All mutations identified were confirmed by resequencing of genomic DNA taken from reserved samples.
###end p 47
###begin p 48
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 360 366 360 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C18">18</xref>
For those samples in which mutations were not detected in the initial phases of analysis, collagen cDNA was prepared, amplified in overlapping fragments of about 1-1.5 kb and examined by PAGE. For sample C2, the cDNA was amplified in two fragments to identify the extent of the genomic deletion. If no mutation was identified in cDNA, genomic DNA of CRTAP and LEPRE1 was amplified as described previously (18) and sequenced.
###end p 48
###begin p 49
###xml 72 110 72 110 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://www.hgvs.org/mutnomen/recs.html">http://www.hgvs.org/mutnomen/recs.html</uri>
###xml 458 464 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 491 497 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 517 523 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 762 768 758 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
Collagen mutations are numbered following the HGVS-approved convention (http://www.hgvs.org/mutnomen/recs.html), which starts with the translation initiator methionine as amino acid +1, and the A of the ATG codon as nucleotide +1. Mutations affecting intronic sequence are referenced to the cDNA sequence. Triple helix positions are provided for amino acids within the triple helical region of each proalpha chain (residues encoded by codons 179-1192 of the COL1A1 transcript and 91-1104 of COL1A2). The exons of the COL1A1 gene are numbered consecutively from 1-32. Exon 33 of the gene is referred to as exon 33-34 by tradition, to allow the codons of the helical domain to be similar between the two genes and exons thereafter continue from 35 to 52. Exons of COL1A2 are numbered consecutively.
###end p 49
###begin p 50
###xml 844 850 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A1</italic>
###xml 880 886 876 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL1A2</italic>
###xml 960 962 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C14">14</xref>
Each identified variation was uniquely classified as either a SNP, causative mutation, or non-synonymous sequence variant of unknown significance. All substitutions for glycine within the triple helical domain, mutations that alter consensus splice sites, insertion or deletion of residues within the triple helical domain, and mutations that result in sequence alterations in the carboxyl-terminal propeptides and that had been previously identified in individuals with OI or shown to alter molecular behavior were considered causative mutations. p.Ala390Thr, p.Glu288Ala, p.Asn855His and p.Pro146Thr in the proalpha1(I) chain are categorized as rare non-synonymous sequence variants of unknown significance. Variations classified as SNPs are detailed in . SNPs include synonymous variations and the non-synonymous rs1800215 (p.Ala1075Thr) in COL1A1 and rs42524 (p.Ala549Pro) in COL1A2. SNPs are considered novel if they are not listed in build 129 of dbSNP (14); novel mutations are those not reported in collagen mutation databases (28, Bodian and Klein, manuscript in preparation).
###end p 50
###begin title 51
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
CRTAP and LEPRE1 mutation detection
###end title 51
###begin p 52
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRTAP</italic>
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LEPRE1</italic>
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C3">3</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C18">18</xref>
Each exon of the CRTAP and LEPRE1 genes was amplified and then sequenced as previously described (3,18). All mutations were confirmed by reamplification and sequencing of a new genomic DNA sample.
###end p 52
###begin title 53
Lethality prediction
###end title 53
###begin p 54
###xml 175 177 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C12">12</xref>
###xml 978 979 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C5">5</xref>
###xml 1128 1130 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C12">12</xref>
Lethality was predicted using a published method applicable to single missense mutations altering the Gly-X-Y glycines in the triple helical region of the proalpha1(I) chain (12). One component of the model is a decision tree that classifies mutations within the N-terminal 178 residues of the triple helix as non-lethal. Mutations C-terminal to position 178 are classified by the amino acid substituting for glycine. Arginine, valine, aspartic acid and glutamic acid substitutions are predicted to be lethal, whereas alanine replacements are predicted to be non-lethal. Cysteine substitutions are tentatively classified as lethal C-terminal to triple helix position 688. Serine substitutions for glycine are classified by a second component based on an estimate of the thermostability of the Gly-X-Y triplet C-terminal to the triplet with the substitution. The models were constructed using the OI triple helical glycine substitutions mutations published by the OI consortium (5) as a training set. Predictions for p.Gly884Ser (Gly706Ser) and p.Gly1094Ser (Gly916Ser) based on preliminary sequencing were published previously (12). For subjects with multiple variations, the triple helical glycine substitutions are assumed to be the primary determinant of OI lethality.
###end p 54
###begin title 55
Statistical analysis
###end title 55
###begin p 56
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN374C29">29</xref>
Confidence intervals were computed using exact distributions as implemented in R (29).
###end p 56
###begin title 57
SUPPLEMENTARY MATERIAL
###end title 57
###begin p 58
.
###end p 58
###begin p 59
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 59
###begin title 60
[Supplementary Data]
###end title 60
###begin title 61
FUNDING
###end title 61
###begin p 62
###xml 31 60 31 60 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institutes of Health</funding-source>
###xml 60 64 60 64 <?release-delay 12|0?>
###xml 66 74 66 74 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR051582</funding-source>
###xml 88 99 88 99 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T32HL007731</award-id>
###xml 268 297 268 297 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institutes of Health</funding-source>
###xml 297 301 297 301 <?release-delay 12|0?>
###xml 162 170 <span type="species:ncbi:9606">Children</span>
This work was supported by the National Institutes of Health12|0 (AR051582 to T.E.K and T32HL007731 to T.F.C); and the Osteogenesis Imperfecta Foundation and the Children's Brittle Bone Foundation (to D.L.B.). Funding to Pay the Open Access Charge was provided by the National Institutes of Health12|0 AR051582.
###end p 62
###begin title 63
REFERENCES
###end title 63
###begin article-title 64
Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta
###end article-title 64
###begin article-title 65
Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta
###end article-title 65
###begin article-title 66
CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta
###end article-title 66
###begin article-title 67
Subtle structural alterations in the chains of type I procollagen produce osteogenesis imperfecta type II
###end article-title 67
###begin article-title 68
Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans
###end article-title 68
###begin article-title 69
Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen
###end article-title 69
###begin article-title 70
Nonsense mutations in the COL1A1 gene preferentially reduce nuclear levels of mRNA but not hnRNA in osteogenesis imperfecta type I cell strains
###end article-title 70
###begin article-title 71
Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains
###end article-title 71
###begin article-title 72
Brittle bones-fragile molecules: disorders of collagen gene structure and expression
###end article-title 72
###begin article-title 73
###xml 123 131 <span type="species:ncbi:9606">patients</span>
BiP binds type I procollagen pro alpha chains with mutations in the carboxyl-terminal propeptide synthesized by cells from patients with osteogenesis imperfecta
###end article-title 73
###begin article-title 74
Mutations in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I collagen result in defective chain association and produce lethal osteogenesis imperfecta
###end article-title 74
###begin article-title 75
Predicting the clinical lethality of osteogenesis imperfecta from collagen glycine mutations
###end article-title 75
###begin article-title 76
###xml 26 31 <span type="species:ncbi:9606">human</span>
Natural variation in four human collagen genes across an ethnically diverse population
###end article-title 76
###begin article-title 77
dbSNP: the NCBI database of genetic variation
###end article-title 77
###begin article-title 78
Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood
###end article-title 78
###begin article-title 79
Deletions and duplications of Gly-Xaa-Yaa triplet repeats in the triple helical domains of type I collagen chains disrupt helix formation and result in several types of osteogenesis imperfecta
###end article-title 79
###begin article-title 80
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV
###end article-title 80
###begin article-title 81
CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta
###end article-title 81
###begin article-title 82
###xml 170 175 <span type="species:ncbi:9606">Human</span>
Carrier Frequency of Recurring Mutation Causing Severe/Lethal Recessive Type VIII Osteogenesis Imperfecta in African-Americans. Annual Meeting of the American Society of Human Genetics, San Diego, California
###end article-title 82
###begin article-title 83
Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development
###end article-title 83
###begin article-title 84
Destabilization of osteogenesis imperfecta collagen-like model peptides correlates with the identity of the residue replacing glycine
###end article-title 84
###begin article-title 85
Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta
###end article-title 85
###begin article-title 86
Heterozygosity for a large deletion in the alpha 2(I) collagen gene has a dramatic effect on type I collagen secretion and produces perinatal lethal osteogenesis imperfecta
###end article-title 86
###begin article-title 87
Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates
###end article-title 87
###begin article-title 88
###xml 102 107 <span type="species:ncbi:9606">human</span>
Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen
###end article-title 88
###begin article-title 89
Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility
###end article-title 89
###begin article-title 90
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human collagen mutation database 1998
###end article-title 90
###begin article-title 91
R: a language and environment for statistical computing
###end article-title 91
###begin article-title 92
###xml 140 148 <span type="species:ncbi:9606">patients</span>
An RT-PCR-SSCP screening strategy for detection of mutations in the gene encoding the alpha 1 chain of type I collagen: application to four patients with osteogenesis imperfecta
###end article-title 92
###begin article-title 93
Mutations that substitute serine for glycine alpha 1-598 and glycine alpha 1-631 in type I procollagen. The effects on thermal unfolding of the triple helix are position-specific and demonstrate that the protein unfolds through a series of cooperative blocks
###end article-title 93
###begin article-title 94
###xml 157 165 153 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Substitution of arginine for glycine 664 in the collagen alpha1(I) chain in lethal perinatal osteogenesis imperfecta. Demonstration of the peptide defect by in vitro expression of the mutant cDNA
###end article-title 94
###begin article-title 95
###xml 86 94 <span type="species:ncbi:9606">children</span>
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
###end article-title 95
###begin article-title 96
Osteogenesis imperfecta: mosaicism and refinement of the genotype-phenotype map in OI type III. Mutations in brief no. 242 (Online)
###end article-title 96
###begin article-title 97
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Two new recurrent nucleotide mutations in the COL1A1 gene in four patients with osteogenesis imperfecta: about one-fifth are recurrent
###end article-title 97
###begin article-title 98
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV
###end article-title 98
###begin article-title 99
Substitution of an aspartic acid for glycine 700 in the alpha 2(I) chain of type I collagen in a recurrent lethal type II osteogenesis imperfecta dramatically affects the mineralization of bone
###end article-title 99
###begin article-title 100
A Gly859Ser substitution in the triple helical domain of the alpha 2 chain of type I collagen resulting in osteogenesis imperfecta type III in two unrelated individuals
###end article-title 100
###begin article-title 101
Osteogenesis imperfecta phenotypes resulting from serine for glycine substitutions in the alpha2(I) collagen chain
###end article-title 101

